Viking Therapeutics Inc.
VKTX | NASDAQ
$39.36
+$9.25 (+30.72%)
Sep 22, 2026, 2:22 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 431K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -431K | n/a | n/a | n/a | n/a | n/a |
Operating Income | -393.34M | -150.92M | -100.83M | -70.36M | -55.68M | -42.66M |
Interest Income | 33.7M | 40.94M | 15.02M | 1.59M | 703K | 3.23M |
Pretax Income | -359.64M | -109.96M | -85.9M | -68.87M | -54.99M | -39.5M |
Net Income | -359.64M | -109.96M | -85.9M | -68.87M | -54.99M | -39.5M |
Selling & General & Admin | 48.39M | 49.28M | 37.02M | 16.12M | 10.7M | 10.73M |
Research & Development | 344.96M | 101.64M | 63.81M | 54.23M | 44.98M | 31.93M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 393.34M | 150.92M | 100.83M | 70.36M | 55.68M | 42.66M |
Interest Expense | 56K | 94K | 88K | 59K | 18K | 106K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 393.34M | 150.92M | 100.83M | 70.36M | 55.68M | 42.66M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 112.67M | 109.04M | 94.35M | 76.83M | 77.2M | 72.6M |
Shares Outstanding (Diluted) | 112.67M | 109.04M | 94.35M | 76.83M | 77.2M | 72.6M |
EPS (Basic) | -3.19 | -1.01 | -0.91 | -0.88 | -0.70 | -0.50 |
EPS (Diluted) | -3.19 | -1.01 | -0.91 | -0.88 | -0.70 | -0.50 |
EBITDA | -359.15M | -109.52M | -85.52M | -68.52M | -54.68M | -39.11M |
EBIT | -359.58M | -109.87M | -85.81M | -68.81M | -54.97M | -39.39M |
Depreciation & Amortization | 431K | 346K | 292K | 291K | 296K | 277K |
Add to Watchlist
Select watchlists to add or remove VKTX